Organization & Developments: Paratek

Parents

Paratek Pharmaceuticals (NASDAQ:PRTK)*

Children

*Developments: Paratek (Archives 2017-2018)
2019: Paratek Pharma Awarded $285 Million BARDA Contract to Combat Anthrax
2019: Paratek’s top antibiotic fails to clear a key competitive hurdle in head-to-head studies – Endpoints News
2019: VA_65--Paratek Pharmaceuticals, Inc. 36F79719D0194 Effective 07/15/2019 -07/14/2024 Effective 07/15/2019
2020: BARDA_Paratek nabs BARDA contract for Nuzyra; shares up 53% premarket
2020: Paratek Pharmaceuticals: An Investment Update
2020: Paratek Pharmaceuticals: Setbacks And Successess_eekingalpha.com
2021: Circling Back On Paratek Pharmaceuticals
2021: Paratek Offers Long-Term Value Potential In The Difficult Antibiotic Business
2021: Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) shares closed the week up 17% to $9.60 following news the FDA approved its supplemental New Drug Application (sNDA) for the oral-only dosing regimen of NUZYRA for the treatment of adults with Community-Acquired Bacterial Pneumonia (CABP).
2021: The Play On Paratek Pharmaceuticals
NUZYRA (omadacycline) is a broad spectrum, novel antibiotic with both once-daily intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections
Paratek has entered into a collaboration agreement with Shanghai-based Zai Lab Ltd. (ZLAB:NASDAQ-ADR) for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.
The company focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States.
These research stage programs include product candidates for multiple sclerosis, spinal muscular atrophy, systemic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel diseases.

Jumps

*Key People: Paratek
Finance & Acquisitions: Paratek

Made with TheBrain